Gender differences in the endotoxin-induced inflammatory and vascular responses:: Potential role of poly(ADP-ribose) polymerase activation

被引:95
作者
Mabley, JG
Horváth, EM
Murthy, KGK
Zsengellér, Z
Vaslin, A
Benkö, R
Kollai, M
Szabó, C
机构
[1] Semmelweis Univ, Sch Med, Dept Human Physiol & Clin Expt Res, H-1082 Budapest, Hungary
[2] Inotek Pharmaceut Corp, Beverly, MA USA
[3] Univ Brighton, Sch Pharm & Biomol Sci, Brighton, E Sussex, England
[4] Univ Med & Dent New Jersey, Dept Surg, Newark, NJ USA
关键词
D O I
10.1124/jpet.105.090480
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Activation of poly(ADP-ribose) polymerase (PARP) is an important factor in the pathogenesis of various cardiovascular and inflammatory diseases. Here, we report that the gender-specific inflammatory response is preferentially down-regulated by PARP in male animals. Female mice produce less tumor necrosis factor-alpha and macrophage inflammatory protein-1 alpha in response to systemic inflammation induced by endotoxin than male mice and are resistant to endotoxin-induced mortality. Pharmacological inhibition of PARP is effective in reducing inflammatory mediator production and mortality in male, but not in female, mice. Ovariectomy partially reverses the protection seen in female mice. Endotoxin-induced PARP activation in circulating leukocytes is reduced in male, but not female, animals by pharmacological PARP inhibition, as shown by flow cytometry. Pretreatment of male mice with 17-beta-estradiol prevents endotoxin-induced hepatic injury and reduces poly(ADP-ribosyl) ation in vivo. In male, but not female, animals, endotoxin induces an impairment of the endothelium-dependent relaxant responses, which is prevented by PARP inhibition. In vitro oxidant-induced PARP activation is reduced in cultured cells placed in female rat serum compared with male serum. Estrogen does not directly inhibit the enzymatic activity of PARP in vitro. However, PARP and estrogen receptor alpha form a complex, which binds to DNA in vitro, and the DNA binding of this complex is enhanced by estrogen. Thus, estrogen may anchor PARP to estrogen receptor alpha and to the DNA and prevent its recognition of DNA strand breaks and hence its activation. In conclusion, the gender difference in the inflammatory response shows preferential modulation by PARP in male animals.
引用
收藏
页码:812 / 820
页数:9
相关论文
共 25 条
  • [1] Effect of gender and sex hormones on immune responses following shock
    Angele, MK
    Schwacha, MG
    Ayala, A
    Chaudry, IH
    [J]. SHOCK, 2000, 14 (02): : 81 - 90
  • [2] Barkhem Tomas, 2004, Am J Pharmacogenomics, V4, P19, DOI 10.2165/00129785-200404010-00003
  • [3] Innate gender-based proclivity in response to cytotoxicity and programmed cell death pathway
    Du, LN
    Bayir, H
    Lai, YC
    Zhang, XP
    Kochanek, PM
    Watkins, SC
    Graham, SH
    Clark, RSB
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2004, 279 (37) : 38563 - 38570
  • [4] Oral hormone replacement therapy: Factors that influence the estradiol concentrations achieved in a multiracial study population
    Gavaler, JS
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 42 (02) : 137 - 144
  • [5] Clinical perspectives of PARP inhibitors
    Graziani, G
    Szabó, C
    [J]. PHARMACOLOGICAL RESEARCH, 2005, 52 (01) : 109 - 118
  • [6] GREENSPAN FS, 2003, BASIC CLIN ENDOCRINO
  • [7] Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion
    Ha, HC
    Snyder, SH
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (24) : 13978 - 13982
  • [8] PARP-1 gene disruption in mice preferentially protects males from perinatal brain injury
    Hagberg, H
    Wilson, MA
    Matsushita, H
    Zhu, CL
    Lange, M
    Gustavsson, M
    Poitras, MF
    Dawson, TM
    Dawson, VL
    Northington, F
    Johnston, MV
    [J]. JOURNAL OF NEUROCHEMISTRY, 2004, 90 (05) : 1068 - 1075
  • [9] HARRIS PE, 2002, ENDOCRINOLOGY CLIN P
  • [10] Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors
    Jagtap, P
    Szabó, C
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (05) : 421 - 440